EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed (www.kinemed.com) announced today that Dr. Patrizia Fanara, Vice President, Neuroscience at KineMed, Inc., will present recent advances in the development of clinically informative biomarkers of neurodegeneration at the CNS Diseases World Summit 2013, September 9-10, Boston, MA www.gtcbio.com/cnssummit/speakers.
“Our unique biomarker platform characterizes human brain function and dysfunction over time and space, mapping disease-related biochemical processes to neuronal subpopulations and linking changes in neuronal function to the evolution of disease”
Dr. Fanara’s presentation, “Translatable Kinetic Biomarkers in CSF to Diagnose and Treat Neurological Disorders” will be given from 5:15 to 5:40 PM EST, on Monday September 9th, in the session titled “Biomarkers: Translation from Discovery to Clinical.”
Dr. Fanara will present results using KineMed’s sophisticated mass spectrometric biomarker platform, generated from a cross-sectional clinical study in patients with Parkinson’s disease. The work is part of a collaborative program with the Michael J. Fox Foundation for Parkinson’s Research.
“Our unique biomarker platform characterizes human brain function and dysfunction over time and space, mapping disease-related biochemical processes to neuronal subpopulations and linking changes in neuronal function to the evolution of disease,” said Dr. Fanara. “KineMed’s platform generates metrics of chemical fluxes in specific neuronal populations in the brain. This approach involves a single sample of cerebrospinal fluid and is superior in many ways to techniques that offer only static metrics, such as the measurement of protein levels. These CSF-based measurements can be used to predict and better understand onset and progression of disease, with the power to drive development of effective therapies for those living with neurodegenerative diseases like PD, AD, HD and ALS.”
Neurodegenerative disorders represent an enormous disease burden. The Parkinson’s Action Network (PAN), www.parkinsonsaction.org, including the Michael J. Fox Foundation for Parkinson’s Research, estimates that current annual cost to provide care for Parkinson’s patients is at least $14.4 billion in the United States, and the prevalence of Parkinson's will more than double by the year 2040. As yet, no cure exists for any major neurodegenerative disease.
About KineMed, Inc.
KineMed is a commercial-stage company with a biomarker platform technology that is potentially transformative for drug development, personalized medicine, and consumer wellness monitoring. KineMed's kinetic biomarkers of personal biology information guide health-related purchases and drug development decisions, transforming the $18B biomarker, $50B diagnostics, and the >$200B consumer wellness markets. KineMed’s biomarker platform provides dynamic molecular information through a proprietary mass spectrometric platform, representing the missing link between individuals and optimal health-related products and services. Active initiatives include non-prescription wellness management, prescription medical needs and the next generation of drug development. These programs provide near-, mid-, and long-term revenues for KineMed from patients, payors, drug developers, consumers and partnerships with consumer companies.
KineMed has developed the first practically useful systems biology technology that can be used directly in humans, with applications not only in drug discovery and development, but also in clinical diagnosis, personalized medicine and therapeutic monitoring, and consumer-wellness decisions. KineMed has three programs based on KineMed’s personal biology information: Rx, Dx/Rx, and Cx:
Therapeutic Drug Discovery and Development (“Rx”)
- Co-development partnerships to improve R&D spend.
Prescription diagnostic tests and test/prescription drug pairings
- For personalized treatment based on disease subtype, optimized clinical management and pairing to the most effective drug therapy for patients.
Non-prescription tests for consumer wellness products (“Cx”)
- Tests that link individuals to over-the-counter products and services and consumer product providers to interested customers.
KineMed’s biomarkers are fully translatable from animal to man across pre-clinical and clinical phases of development. This platform applies to diagnosis and management across the spectrum of diseases, including conditions involving fibrosis, neurodegeneration, muscle loss, metabolic cardiovascular or dermatologic disorders and cancer, as well as consumer wellness.
Over the past few years, KineMed has changed both textbook thought about diseases and the development path of several drug candidates. Notable accomplishments include:
- Transforming the pathogenic model of chronic lymphocytic leukemia (CLL)
- Developing the first blood-based biomarker of tissue fibrogenesis in humans
- Generating the first accurate non-invasive laboratory biomarkers of muscle mass and muscle quality in humans
- Creating the first diagnostic tests of disease-modifying processes in a neurodegenerative disease (Parkinson’s disease)
- Developing a “tachometer” of reverse cholesterol transport and metrics of plasma lipid dynamics
- Identifying new, secondary indications for drug candidates in Pharma pipelines
- Identifying new targets for drug development in several important diseases
For more information about KineMed, please visit: www.kinemed.com